{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:18:47Z","timestamp":1773220727451,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Youth Natural Science Foundation of Shandong Province","award":["No. ZR2023QH128"],"award-info":[{"award-number":["No. ZR2023QH128"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82373000"],"award-info":[{"award-number":["No. 82373000"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04207-8","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T05:54:35Z","timestamp":1770357275000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the safety and efficacy of different neoadjuvant therapy cycles for locally advanced gastric cancer: a retrospective propensity score-matched cohort study"],"prefix":"10.1186","volume":"24","author":[{"given":"Zhihua","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haolin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"4207_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"4207_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01451-3","volume":"16","author":"W-L Guan","year":"2023","unstructured":"Guan W-L, He Y, Xu R-H. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16:57. https:\/\/doi.org\/10.1186\/s13045-023-01451-3.","journal-title":"J Hematol Oncol"},{"key":"4207_CR3","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/cac2.12197","volume":"41","author":"H Qiu","year":"2021","unstructured":"Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun. 2021;41:1037\u201348. https:\/\/doi.org\/10.1002\/cac2.12197.","journal-title":"Cancer Commun"},{"key":"4207_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"F-H Wang","year":"2023","unstructured":"Wang F-H, Zhang X-T, Tang L, Wu Q, Cai M-Y, Li Y-F, et al. The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun. 2023;44:127\u201372. https:\/\/doi.org\/10.1002\/cac2.12516.","journal-title":"Cancer Commun"},{"key":"4207_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","volume":"23","author":"JA Ajani","year":"2025","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Corvera CU, Das P, Enzinger PC, et al. Gastric cancer, version 2.2025, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2025;23:169\u201391. https:\/\/doi.org\/10.6004\/jnccn.2025.0022.","journal-title":"J Natl Compr Canc Netw"},{"key":"4207_CR6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, Van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(20)31288-5.","journal-title":"Lancet"},{"key":"4207_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320. https:\/\/doi.org\/10.1056\/NEJMoa055531.","journal-title":"N Engl J Med"},{"key":"4207_CR8","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22:1081\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(21)00297-7.","journal-title":"Lancet Oncol"},{"key":"4207_CR9","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.20.02914","volume":"39","author":"Y-K Kang","year":"2021","unstructured":"Kang Y-K, Yook JH, Park Y-K, Lee JS, Kim Y-W, Kim JY, et al. PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39:2903\u201313. https:\/\/doi.org\/10.1200\/JCO.20.02914.","journal-title":"J Clin Oncol"},{"key":"4207_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13643-022-02001-7","volume":"11","author":"J Hu","year":"2022","unstructured":"Hu J, Yang Y, Ma Y, Ning Y, Chen G, Liu Y. Survival benefits from neoadjuvant treatment in gastric cancer: a systematic review and meta-analysis. Syst Rev. 2022;11:136. https:\/\/doi.org\/10.1186\/s13643-022-02001-7.","journal-title":"Syst Rev"},{"key":"4207_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1470-2045(09)70021-X","volume":"10","author":"D D\u2019Ugo","year":"2009","unstructured":"D\u2019Ugo D, Rausei S, Biondi A, Persiani R. Preoperative treatment and surgery in gastric cancer: friends or foes? Lancet Oncol. 2009;10:191\u20135. https:\/\/doi.org\/10.1016\/S1470-2045(09)70021-X.","journal-title":"Lancet Oncol"},{"key":"4207_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/09540105.2024.2442369","volume":"35","author":"X Zeng","year":"2024","unstructured":"Zeng X, Wu Z, Pan Y, Ma Y, Chen Y, Zhao Z. Effects of micronutrients and macronutrients on risk of allergic disease in the European population: a Mendelian randomization study. Food Agric Immunol. 2024;35:2442369. https:\/\/doi.org\/10.1080\/09540105.2024.2442369.","journal-title":"Food Agric Immunol"},{"key":"4207_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-15309-w","volume":"15","author":"K Wang","year":"2025","unstructured":"Wang K, Li K, Zhang Z, Zeng X, Wu Z, Zhang B, et al. Combined preoperative platelet-albumin ratio and cancer inflammation prognostic index predicts prognosis in colorectal cancer: a retrospective study. Sci Rep. 2025;15:29500. https:\/\/doi.org\/10.1038\/s41598-025-15309-w.","journal-title":"Sci Rep"},{"key":"4207_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"4207_CR15","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s10120-015-0490-3","volume":"19","author":"Y-W Kim","year":"2015","unstructured":"Kim Y-W, Kim M-J, Ryu KW, Lim H-S, Lee JH, Kong S-Y, et al. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival. Gastric Cancer. 2015;19:586\u201396. https:\/\/doi.org\/10.1007\/s10120-015-0490-3.","journal-title":"Gastric Cancer"},{"key":"4207_CR16","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1038\/bjc.2016.126","volume":"114","author":"X Wang","year":"2016","unstructured":"Wang X, Zhao L, Liu H, Zhong D, Liu W, Shan G, et al. A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer. Br J Cancer. 2016;114:1326\u201333. https:\/\/doi.org\/10.1038\/bjc.2016.126.","journal-title":"Br J Cancer"},{"key":"4207_CR17","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1007\/s10120-022-01314-9","volume":"25","author":"G Grizzi","year":"2022","unstructured":"Grizzi G, Petrelli F, Di Bartolomeo M, Viti M, Texeira Moraes M, Luciani A, et al. Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis. Gastric Cancer. 2022;25:982\u20137. https:\/\/doi.org\/10.1007\/s10120-022-01314-9.","journal-title":"Gastric Cancer"},{"key":"4207_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25:212\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(23)00541-7.","journal-title":"Lancet Oncol"},{"key":"4207_CR19","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","volume":"29","author":"M Ychou","year":"2011","unstructured":"Ychou M, Boige V, Pignon J-P, Conroy T, Bouch\u00e9 O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715\u201321. https:\/\/doi.org\/10.1200\/JCO.2010.33.0597.","journal-title":"J Clin Oncol"},{"key":"4207_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejca.2016.04.012","volume":"62","author":"T Yoshikawa","year":"2016","unstructured":"Yoshikawa T, Morita S, Tanabe K, Nishikawa K, Ito Y, Matsui T, et al. Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer. Eur J Cancer. 2016;62:103\u201311. https:\/\/doi.org\/10.1016\/j.ejca.2016.04.012.","journal-title":"Eur J Cancer"},{"key":"4207_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1245\/s10434-013-3055-x","volume":"21","author":"T Yoshikawa","year":"2013","unstructured":"Yoshikawa T, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, et al. Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS trial. Ann Surg Oncol. 2013;21:213\u20139. https:\/\/doi.org\/10.1245\/s10434-013-3055-x.","journal-title":"Ann Surg Oncol"},{"key":"4207_CR22","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1007\/s10120-019-00941-z","volume":"22","author":"M Terashima","year":"2019","unstructured":"Terashima M, Iwasaki Y, Mizusawa J, Katayama H, Nakamura K, Katai H, et al. Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). Gastric Cancer. 2019;22:1044\u201352. https:\/\/doi.org\/10.1007\/s10120-019-00941-z.","journal-title":"Gastric Cancer"},{"key":"4207_CR23","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1093\/annonc\/mdx236","volume":"28","author":"T Aoyama","year":"2017","unstructured":"Aoyama T, Nishikawa K, Fujitani K, Tanabe K, Ito S, Matsui T, et al. Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin\/S-1 and docetaxel\/cisplatin\/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer. Ann Oncol. 2017;28:1876\u201381. https:\/\/doi.org\/10.1093\/annonc\/mdx236.","journal-title":"Ann Oncol"},{"key":"4207_CR24","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00595-020-02179-0","volume":"51","author":"S Umeda","year":"2020","unstructured":"Umeda S, Kanda M, Nakanishi K, Ito S, Mochizuki Y, Teramoto H, et al. Short-term outcomes of gastrectomy after neoadjuvant chemotherapy for clinical stage III gastric cancer: propensity score-matched analysis of a multi-institutional database. Surg Today. 2020;51:821\u20138. https:\/\/doi.org\/10.1007\/s00595-020-02179-0.","journal-title":"Surg Today"},{"key":"4207_CR25","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/bjs.10836","volume":"105","author":"SD Nelen","year":"2018","unstructured":"Nelen SD, Bosscha K, Lemmens VEPP, Hartgrink HH, Verhoeven RHA, et al. Morbidity and mortality according to age following gastrectomy for gastric cancer. Br J Surg. 2018;105:1163\u201370. https:\/\/doi.org\/10.1002\/bjs.10836.","journal-title":"Br J Surg"},{"key":"4207_CR26","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1038\/sj.bjc.6602572","volume":"92","author":"K Sumpter","year":"2005","unstructured":"Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer. 2005;92:1976\u201383. https:\/\/doi.org\/10.1038\/sj.bjc.6602572.","journal-title":"Br J Cancer"},{"key":"4207_CR27","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/jso.23009","volume":"105","author":"Z Li","year":"2011","unstructured":"Li Z, Koh CE, Bu Z, Wu A, Zhang L, Wu X, et al. Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer. J Surg Oncol. 2011;105:793\u20139. https:\/\/doi.org\/10.1002\/jso.23009.","journal-title":"J Surg Oncol"},{"key":"4207_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/COC.0000000000000058","volume":"40","author":"M Kochi","year":"2017","unstructured":"Kochi M, Fujii M, Kanamori N, Mihara Y, Funada T, Tamegai H, et al. Phase II study of neoadjuvant chemotherapy with S-1 and CDDP in patients with lymph node metastatic stage II or III gastric cancer. Am J Clin Oncol. 2017;40:17\u201321. https:\/\/doi.org\/10.1097\/COC.0000000000000058.","journal-title":"Am J Clin Oncol"},{"key":"4207_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"key":"4207_CR30","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1007\/s00277-021-04562-4","volume":"100","author":"L Yin","year":"2021","unstructured":"Yin L, Xie S, Chen Y, Li W, Jiang X, Li H, et al. Novel germline mutation KMT2A G3131S confers genetic susceptibility to familial myeloproliferative neoplasms. Ann Hematol. 2021;100:2229\u201340. https:\/\/doi.org\/10.1007\/s00277-021-04562-4.","journal-title":"Ann Hematol"},{"key":"4207_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1164692","volume":"14","author":"H Zhang","year":"2023","unstructured":"Zhang H, Shi Y, Ying J, Chen Y, Guo R, Zhao X, et al. A bibliometric and visualized research on global trends of immune checkpoint inhibitors related complications in melanoma, 2011\u20132021. Front Endocrinol. 2023;14:1164692. https:\/\/doi.org\/10.3389\/fendo.2023.1164692.","journal-title":"Front Endocrinol"},{"key":"4207_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02811-w","volume":"16","author":"Y Chen","year":"2025","unstructured":"Chen Y, Anwar M, Wang X, Zhang B, Ma B. Integrative transcriptomic and single-cell analysis reveals IL27RA as a key immune regulator and therapeutic indicator in breast cancer. Discov Oncol. 2025;16:977. https:\/\/doi.org\/10.1007\/s12672-025-02811-w.","journal-title":"Discov Oncol"},{"key":"4207_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-03068-z","volume":"16","author":"B Li","year":"2025","unstructured":"Li B, Lin R, Hua Y, Ma B, Chen Y. Single-cell RNA sequencing reveals TMEM71 as an immunomodulatory biomarker predicting immune checkpoint blockade response in breast cancer. Discov Oncol. 2025;16:1256. https:\/\/doi.org\/10.1007\/s12672-025-03068-z.","journal-title":"Discov Oncol"},{"key":"4207_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71317","volume":"14","author":"Y Chen","year":"2025","unstructured":"Chen Y, Bai M, Liu M, Zhang Z, Jiang C, Li K, et al. Metabolic reprogramming in lung cancer: hallmarks, mechanisms, and targeted strategies to overcome immune resistance. Cancer Med. 2025;14:e71317. https:\/\/doi.org\/10.1002\/cam4.71317.","journal-title":"Cancer Med"},{"key":"4207_CR35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3748\/wjg.v24.i2.257","volume":"24","author":"Y Liu","year":"2018","unstructured":"Liu Y, Zhang K-C, Huang X-H, Xi H-Q, Gao Y-H, Liang W-Q, et al. Timing of surgery after neoadjuvant chemotherapy for gastric cancer: impact on outcomes. World J Gastroenterol. 2018;24:257\u201365. https:\/\/doi.org\/10.3748\/wjg.v24.i2.257.","journal-title":"World J Gastroenterol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04207-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04207-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04207-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T11:38:30Z","timestamp":1773142710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04207-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4207"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04207-8","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the Ethics Committee of Qilu Hospital of Shandong University (No. KYLL-202501-049-1), which waived the requirement for individual consent due to its retrospective design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors gave consent for the publication of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}